Peptide Firms Are Moving Fast While FDA Decision Remains on Hold, Raising Patient Risk Concerns
Peptide companies are moving quickly to expand their offerings while a final decision from the US Food and Drug Administration (FDA) is still pending, raising concerns among health experts about potential risks to patients. Last month, an FDA advisory panel recommended easing restrictions on certain peptides, ...